IP Library › Granted Patent US 11,028,099
Granted Patent B2
US 11,028,099 · App. 16/469,203 · Granted Jun 8, 2021

NRF2 activators

Inventors: Carl A. Brooks (King of Prussia, PA); Jay M. Matthews (King of Prussia, PA)
Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
C07D498/04A61K9/007A61K9/0019A61K9/0053C07C215/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,028,099
App. No.
16/469,203
Granted
Jun 8, 2021
Kind
B2
Abstract

The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator.

Claims (3)

1. A compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable excipients.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2019
From: BROOKS, CARL A.; MATTHEWS, JAY M.
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 049455/0863 →
Continuity (2)
Provisional Application 62434745 · Dec 15, 2016
Related Publication 20200031846A1 · Jan 30, 2020